Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.73M Buy
6,598
+1,366
+26% +$350K 0.81% 32
2026
Q2
$1.32M Buy
5,232
+161
+3% +$34.6K 0.72% 32
2026
Q1
$1.1M Sell
5,071
-993
-16% -$220K 0.72% 31
2025
Q4
$1.39M Buy
6,064
+36
+0.6% +$8.2K 1.06% 22
2025
Q3
$1.4M Buy
6,028
+199
+3% +$40.5K 1.07% 19
2025
Q2
$1.08M Buy
5,829
+878
+18% +$163K 0.87% 27
2025
Q1
$1.04M Buy
4,951
+1,995
+67% +$388K 1.04% 17
2024
Q4
$525K Buy
+2,956
New +$543K 0.51% 49

Other funds holding ABBV

PUREfi Wealth's ABBV Position: Q3 2026 in Review

PUREfi Wealth increased its AbbVie (ABBV) stake by 26% in Q3 2026, buying an estimated $350K and bringing the position to 6,598 shares worth $1.73M. The position accounts for 0.81% of the portfolio, ranked #32.

PUREfi Wealth first reported a position in ABBV in Q4 2024 and has held it in 8 quarters since. 921 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • PUREfi Wealth held 6,598 shares of AbbVie worth $1.73M as of Q3 2026.
  • PUREfi Wealth bought 1,366 AbbVie shares in Q3 2026, an estimated $350K.
  • AbbVie made up 0.81% of PUREfi Wealth's portfolio in Q3 2026, its #32 holding.
  • PUREfi Wealth first reported a position in AbbVie in Q4 2024 and has held it in 8 quarters since.
  • 921 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on PUREfi Wealth's 13F filing for Q3 2026, filed 19 Oct 2026.